

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

## **1. NAME OF THE MEDICINAL PRODUCT**

IMVANEX suspension for injection  
Smallpox vaccine (Live Modified Vaccinia Virus Ankara)

## **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

One dose (0.5 ml) contains:

Modified Vaccinia Ankara – Bavarian Nordic Live virus<sup>1</sup> no less than  $5 \times 10^7$  Inf.U \*

\*infectious units

<sup>1</sup> Produced in chick embryo cells

This vaccine contains trace residues of gentamicin (see section 4.3).

For the full list of excipients, see section 6.1.

## **3. PHARMACEUTICAL FORM**

Suspension for injection.

Pale milky coloured homogeneous suspension.

## **4. CLINICAL PARTICULARS**

### **4.1 Therapeutic indications**

Active immunisation against smallpox in adults (see sections 4.4 and 5.1).

The use of this vaccine should be in accordance with official recommendations.

### **4.2 Posology and method of administration**

#### Posology

#### Primary vaccination (individuals previously not vaccinated against smallpox):

A first dose of 0.5 ml should be administered on an elected date.

A second dose of 0.5 ml should be administered no less than 28 days after the first dose.

See sections 4.4 and 5.1.

#### Booster vaccination (individuals previously vaccinated against smallpox):

There are inadequate data to determine the appropriate timing of booster doses. If a booster dose is considered necessary then a single dose of 0.5 ml should be administered.

See sections 4.4 and 5.1.

#### Special population:

Immunocompromised patients (e.g. HIV infected, patients under immunosuppressive therapy) who have been previously vaccinated against smallpox should receive two booster doses. The second booster vaccination should be given no less than 28 days after the first dose.

#### Paediatric population

The safety and efficacy of IMVANEX in individuals below 18 years of age have not been established.

#### Method of administration

Immunisation should be carried out by subcutaneous injection, preferably into the upper arm (deltoid).

For instructions on administration, see section 6.6.

### **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 or trace residues (chicken protein, benzonase and gentamicin).

### **4.4 Special warnings and precautions for use**

As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine.

Immunisation should be postponed in individuals suffering from an acute severe febrile illness or acute infection. The presence of a minor infection and/or low-grade fever should not result in the deferral of vaccination.

IMVANEX should not be administered by intravascular injection.

The protective efficacy of IMVANEX against smallpox has not been studied. See section 5.1.

A protective immune response may not be elicited in all vaccinees.

There are inadequate data to determine the appropriate timing of booster doses.

Prior vaccination with IMVANEX may modify the cutaneous response ('take') to subsequently administered replication-competent smallpox vaccine resulting in a reduced or absent take.

Individuals with atopic dermatitis developed more local and general symptoms after vaccination (see section 4.8)

Data have been generated in HIV infected individuals with CD4 counts  $\geq 200$  cells/ $\mu$ l and  $\leq 750$  cells/ $\mu$ l. Lower immune response data have been observed in HIV infected individuals compared to healthy individuals (see section 5.1). There are no data on the immune response to IMVANEX in other immunosuppressed individuals.

Two doses of IMVANEX given at a 7-day interval showed lower immune responses and slightly more local reactogenicity than two doses given at a 28-day interval. Therefore, dose intervals of less than 4 weeks should be avoided.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

No interaction studies with other vaccines or medicinal products have been performed. Therefore, concomitant administration of IMVANEX with other vaccines should be avoided. The concomitant administration of the vaccine with any immunoglobulin including Vaccinia Immune Globulin (VIG) has not been studied and should be avoided.

#### **4.6 Fertility, pregnancy and lactation**

##### Pregnancy

There are limited data (less than 300 pregnancy outcomes) from the use of IMVANEX in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). As a precautionary measure the use of IMVANEX should be avoided during pregnancy unless it is considered that the possible benefit in terms of preventing smallpox would outweigh the potential risk.

##### Breast-feeding

It is not known whether IMVANEX is excreted in human milk.

IMVANEX should be avoided during breastfeeding unless it is considered that the possible benefit in terms of preventing smallpox would outweigh the potential risk.

##### Fertility

Animal studies did not reveal any evidence of impaired female and male fertility.

#### **4.7 Effects on ability to drive and use machines**

Some of the undesirable effects mentioned in section 4.8 may affect the ability to drive or operate machinery (e.g. dizziness).

#### **4.8 Undesirable effects**

##### Summary of the safety profile

The safety of IMVANEX has been assessed in 18 clinical trials in which 5,028 Vaccinia-naïve individuals received two doses  $1 \times 10^8$  Inf.U four weeks apart while 534 Vaccinia- and IMVANEX-experienced individuals received a single booster dose.

The most common adverse reactions observed in clinical trials were injection site reactions and common systemic reactions typical for vaccines which were mild to moderate in intensity and resolved without intervention within seven days following vaccination.

Adverse reaction rates reported after either vaccination dose (1<sup>st</sup>, 2<sup>nd</sup> or booster) were similar.

##### Tabulated summary of adverse reactions

Adverse reactions from all clinical trials are listed according to the following frequency:

Very common ( $\geq 1/10$ )

Common ( $\geq 1/100$  to  $< 1/10$ )

Uncommon ( $\geq 1/1,000$  to  $< 1/100$ )

Rare ( $\geq 1/10,000$  to  $< 1/1,000$ )

**Table 1: Adverse Reactions Reported in Completed Clinical Trials with IMVANEX (N = 6,775 subjects)**

| MedDRA System Organ Class                            | Very common (≥1/10)  | Common (≥1/100 to <1/10)   | Uncommon (≥1/1,000 to <1/100)  | Rare (≥1/10,000 to <1/1,000)   |
|--|--|--|--|--|
| Infections and Infestations                          | -  | -  | Nasopharyngitis<br>Upper respiratory tract infection   | Sinusitis<br>Conjunctivitis<br>Influenza   |
| Blood and Lymphatic System Disorders                 | -  | -  | Lymphadenopathy  | -  |
| Metabolism and Nutrition Disorders                   | -  | Appetite disorder  | -  | -  |
| Psychiatric Disorders                                | -  | -  | Sleep disorder   | -  |
| Nervous System Disorders                             | Headache   | -  | Dizziness<br>Paresthesia   | Migraine<br>Peripheral sensory neuropathy<br>Somnolence  |
| Ear and Labyrinth Disorders                          | -  | -  | -  | Vertigo  |
| Cardiac Disorders                                    | -  | -  | -  | Tachycardia  |
| Respiratory, Thoracic and Mediastinal Disorders      | -  | -  | Pharyngolaryngeal pain<br>Rhinitis<br>Cough  | -  |
| Gastrointestinal Disorders                           | Nausea   | -  | Diarrhoea<br>Vomiting<br>Abdominal Pain<br>Dry mouth   | -  |
| Skin and Subcutaneous Tissue Disorders               | -  | -  | Rash<br>Pruritus<br>Dermatitis<br>Skin discolouration  | Urticaria<br>Ecchymosis<br>Hyperhidrosis<br>Night sweats<br>Subcutaneous nodule<br>Angioedema  |
| Musculoskeletal and Connective Tissue Disorders      | Myalgia  | Pain in extremity<br>Arthralgia  | Musculoskeletal stiffness<br>Back pain<br>Neck pain  | Muscle spasms<br>Musculoskeletal pain<br>Muscular weakness   |
| General Disorders and Administration Site Conditions | Injection site pain<br>Injection site erythema<br>Injection site swelling<br>Injection site induration | Rigor/Chills<br>Injection site discolouration<br>Injection site nodule<br>Injection site haematoma | Underarm swelling<br>Injection site warmth<br>Injection site haemorrhage<br>Injection site irritation<br>Flushing<br>Chest pain<br>Axillary pain | Injection site rash<br>Oedema peripheral<br>Asthenia<br>Injection site anesthesia<br>Injection site dryness<br>Injection site movement impairment<br>Malaise |

| MedDRA System Organ Class                      | Very common (≥1/10)                | Common (≥1/100 to <1/10)              | Uncommon (≥1/1,000 to <1/100)  | Rare (≥1/10,000 to <1/1,000)                      |
|--|------------------------------------|---------------------------------------|--|---|
|  | Injection site pruritus<br>Fatigue |                                       | Injection site exfoliation<br>Injection site inflammation<br>Injection site paraesthesia<br>Injection site reaction    | Influenza like illness<br>Injection site vesicles |
| Investigations                                 | -                                  | Body temperature increased<br>Pyrexia | Troponin I increased<br>Hepatic enzyme increased<br>White blood cell count decreased<br>Mean platelet volume decreased | White blood cell count increased                  |
| Injury, Poisoning and Procedural Complications | -                                  | -                                     | Contusion  | -   |

#### Individuals with atopic dermatitis (AD)

In a non-placebo controlled clinical trial that compared the safety of IMVANEX in individuals with AD to healthy individuals, individuals with AD reported erythema (61.2%) and swelling (52.2%) at the injection site with a higher frequency than healthy individuals (49.3% and 40.8%, respectively). The following general symptoms were reported more frequently in individuals with AD compared to healthy individuals: headache (33.1% vs. 24.8%), myalgia (31.8% vs. 22.3%), chills (10.7% vs. 3.8 %), nausea (11.9% vs. 6.8%), and fatigue (21.4% vs. 14.4%).

7% of the individuals with AD in clinical trials with IMVANEX experienced a flare-up or worsening of their skin condition during the course of the trial.

#### Rash

IMVANEX may trigger local rashes or more widespread eruptions. Events of rash after vaccination (related cases observed in 0.64% of subjects) with IMVANEX tend to occur within the first days after vaccination, are mild to moderate in intensity and usually resolve without sequelae.

#### Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in [Appendix V](#).

## 4.9 Overdose

No case of overdose has been reported.

## 5. PHARMACOLOGICAL PROPERTIES

### 5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Vaccine, other viral vaccines, ATC code: J07BX

#### Efficacy in animals

Non-human primate (NHP) studies have demonstrated that vaccination with IMVANEX induced a comparable immune response and protective efficacy to traditional smallpox vaccines used to eradicate smallpox and protected NHP from severe disease associated with a lethal challenge of monkeypox virus. As seen with traditional smallpox vaccines, a significant reduction in both mortality and morbidity (viral load, weight loss, number of pox lesions, etc.) compared to non-vaccinated controls was demonstrated for NHP vaccinated with IMVANEX.

#### Immunogenicity in humans

##### Seroconversion rates in Vaccinia-naïve healthy and special populations

The Vaccinia-naïve study population included healthy individuals as well as individuals with HIV infection and AD who received 2 doses of IMVANEX 4 weeks apart. Seroconversion rates in Vaccinia-naïve individuals were defined as appearance of antibody titers equal or greater than the assay cut-off value following receipt of two doses of IMVANEX. Seroconversion by ELISA and PRNT were as follows:

| SCR - ELISA              |               |                   | Day 7/14 <sup>1</sup> | Day 28 <sup>1</sup> | Day 42 <sup>1</sup> |
|--------------------------|---------------|-------------------|-----------------------|---------------------|---------------------|
| Study                    | Health status | N                 | SCR % (95% CI)        | SCR % (95% CI)      | SCR % (95% CI)      |
| POX-MVA-005 <sup>2</sup> | Healthy       | 183               | 70.9 (63.7,77.4)      | 88.9 (83.4, 93.1)   | 98.9 (96.0,99.9)    |
| POX-MVA-008 <sup>3</sup> | Healthy       | 194               | 12.5 (8.1, 18.2)      | 85.4 (79.6, 90.1)   | 98.5 (95.5, 99.7)   |
|                          | AD            | 257               | 22.9 (17.8, 28.6)     | 85.4 (80.5, 89.5)   | 97.3 (94.5, 98.9)   |
| POX-MVA-009 <sup>4</sup> | Healthy       | 66                | 69.7 (57.1, 80.4)     | 72.2 (60.4, 83.0)   | 96.8 (89.0, 99.6)   |
| POX-MVA-011 <sup>2</sup> | Healthy       | 88                | 29.6 (20.0, 40.8)     | 83.7 (74.2, 90.8)   | 98.7 (93.1, 100)    |
|                          | HIV           | 351               | 29.2 (24.3, 34.5)     | 67.5 (62.1, 72.5)   | 96.2 (93.4, 98.0)   |
| POX-MVA-013 <sup>2</sup> | Healthy       | 2119 <sup>6</sup> | N/A <sup>5</sup>      | N/A <sup>5</sup>    | 99.7 (99.4; 99.9)   |

| SCR - PRNT               |               |                   | Day 7/14 <sup>1</sup> | Day 28 <sup>1</sup> | Day 42 <sup>1</sup> |
|--------------------------|---------------|-------------------|-----------------------|---------------------|---------------------|
| Study                    | Health Status | N                 | SCR % (95% CI)        | SCR % (95% CI)      | SCR % (95% CI)      |
| POX-MVA-005 <sup>2</sup> | Healthy       | 183               | 45.1 (37.7, 52.6)     | 56.7 (49.1, 64.0)   | 89.2 (83.7, 93.4)   |
| POX-MVA-008 <sup>3</sup> | Healthy       | 194               | 5.4 (2.6, 9.8)        | 24.5 (18.6, 31.2)   | 86.6 (81.0, 91.1)   |
|                          | AD            | 257               | 5.6 (3.1, 9.3)        | 26.8 (21.4, 32.7)   | 90.3 (86.0, 93.6)   |
| POX-MVA-009 <sup>4</sup> | Healthy       | 66                | 12.1 (5.4, 22.5)      | 10.6 (4.4, 20.6)    | 82.5 (70.9, 90.9)   |
| POX-MVA-011 <sup>2</sup> | Healthy       | 88                | 11.1 (5.2, 20.0)      | 20.9 (12.9, 31.0)   | 77.2 (66.4, 85.9)   |
|                          | HIV           | 351               | 15.7 (11.9, 20.1)     | 22.5 (18.1, 27.4)   | 60.3 (54.7, 65.8)   |
| POX-MVA-013 <sup>2</sup> | Healthy       | 2119 <sup>6</sup> | N/A <sup>5</sup>      | N/A <sup>5</sup>    | 99.8 (99.5; 99.9)   |

<sup>1</sup>Day 7/14 corresponding to 1 or 2 weeks after the first IMVANEX dose (analysis time point at Day 7 only in studies POX-MVA-008 and POX-MVA-011; POX-MVA-005 had the first post vaccination analysis at Day 14); Day 28 corresponding to 4 weeks after the first IMVANEX dose; Day 42 corresponding to 2 weeks following the second dose of IMVANEX; SCR = Seroconversion rate;

<sup>2</sup> Full Analysis Set (FAS) (for POX-MVA-013: Immunogenicity Analysis Set; IAS); <sup>3</sup> Per Protocol Analysis Set (PPS),

<sup>4</sup> seropositivity rates, <sup>5</sup> no immunogenicity sample taken, <sup>6</sup> combined Groups 1-3

### Seroconversion rates in Vaccinia-experienced healthy and special populations

Seroconversion in Vaccinia-experienced individuals was defined as at least a two-fold increase in base titres following a single vaccination with IMVANEX.

| SCR - ELISA              |               |     | Day 0 <sup>1</sup> | Day 7/14 <sup>1</sup> | Day 28 <sup>1</sup> | Day 42 <sup>1</sup> |
|--------------------------|---------------|-----|--------------------|-----------------------|---------------------|---------------------|
| Study                    | Health status | N   | SCR %              | SCR % (95% CI)        | SCR % (95% CI)      | SCR % (95% CI)      |
| POX-MVA-005 <sup>2</sup> | Healthy       | 200 | -                  | 95.5 (91.6, 97.9)     | 93.0 (88.5, 96.1)   | NA                  |
| POX-MVA-024 <sup>2</sup> | Healthy       | 61  | -                  | 83.6 (71.9, 91.8)     | 79.7 (67.2, 89.0)   | NA                  |
| POX-MVA-011 <sup>2</sup> | Healthy       | 9   | -                  | 62.5 (24.5, 91.5)     | 100 (63.1, 100)     | 100 (59.0, 100.0)   |
|                          | HIV           | 131 | -                  | 57.3 (48.1, 66.1)     | 76.6 (68.2, 83.7)   | 92.7 (86.6, 96.6)   |

| SCR - PRNT               |               |     | Day 0 <sup>1</sup> | Day 7/14 <sup>1</sup> | Day 28 <sup>1</sup> | Day 42 <sup>1</sup> |
|--------------------------|---------------|-----|--------------------|-----------------------|---------------------|---------------------|
| Study                    | Health status | N   | SCR %              | SCR % (95% CI)        | SCR % (95% CI)      | SCR % (95% CI)      |
| POX-MVA-005 <sup>2</sup> | Healthy       | 200 | -                  | 78.5 (72.2, 84.0)     | 69.8 (63.0, 76.1)   | NA                  |
| POX-MVA-024 <sup>2</sup> | Healthy       | 61  | -                  | 73.8 (60.9, 84.2)     | 71.2 (57.9, 82.2)   | NA                  |
| POX-MVA-011 <sup>2</sup> | Healthy       | 9   | -                  | 75.0 (34.9, 96.8)     | 62.5 (24.5, 91.5)   | 85.7 (42.1, 99.6)   |
|                          | HIV           | 131 | -                  | 46.0 (37.0, 55.1)     | 59.7 (50.5, 68.4)   | 75.6 (67.0, 82.9)   |

<sup>1</sup>Day 0 corresponding to day of vaccination with IMVANEX; Day 7/14 corresponding to 1 or 2 weeks after vaccination with IMVANEX (first post vaccination analysis at Day 7 in study POX-MVA-011, and at Day 14 in studies POX-MVA-005 and POX-MVA-024); Day 28 corresponding to 4 weeks after vaccination with IMVANEX; SCR = Seroconversion rate; <sup>2</sup> Full Analysis Set (FAS);

### Long-term immunogenicity in humans

Limited data on long-term immunogenicity covering a period of 24 months following primary vaccination of Vaccinia-naïve individuals with IMVANEX are currently available as shown below:

| Month | N   | ELISA                |                         | PRNT                 |                      |
|-------|-----|----------------------|-------------------------|----------------------|----------------------|
|       |     | SCR % (95% CI)       | GMT (95% CI)            | SCR % (95% CI)       | GMT (95% CI)         |
| 2     | 178 | 98.9<br>(96.0, 99.9) | 328.7<br>(288.5, 374.4) | 86.0<br>(80.0, 90.7) | 34.0<br>(26.4, 43.9) |
| 6     | 178 | 73.0<br>(65.9, 79.4) | 27.9<br>(20.7, 37.6)    | 65.2<br>(57.7, 72.1) | 7.2<br>(5.6, 9.4)    |
| 24*   | 92  | 71.7<br>(61.4, 80.6) | 23.3<br>(15.2, 35.9)    | 5.4<br>(1.8, 12.2)   | 1.3<br>(1.0, 1.5)    |

ELISA = enzyme-linked immunosorbent assay; GMT= geometric mean titre; N = number of subjects in the specific study group; PRNT = plaque reduction neutralisation test; SCR = seroconversion rate;

\*represents seropositivity rates

### Booster Dose

Two clinical studies have demonstrated that IMVANEX is able to boost a pre-existing immunological memory response, induced by either licensed smallpox vaccines a long time ago or two years after IMVANEX.



| Primary immunisation      | ELISA | N   | Day 0 <sup>1</sup> |     | N   | Day 7 <sup>1</sup> |     | Day 14 <sup>1</sup> |      |
|---------------------------|-------|-----|--------------------|-----|-----|--------------------|-----|---------------------|------|
|                           |       |     | S+ %               | GMT |     | S+ %               | GMT | S+ %                | GMT  |
| 2 doses of IMVANEX        |       | 92  | 72                 | 23  | 75  | 100                | 738 | 100                 | 1688 |
| Licensed smallpox vaccine |       | 200 | 79                 | 39  | 195 | -                  | -   | 98                  | 621  |
|                           | PRNT  | N   | S+ %               | GMT | N   | S+ %               | GMT | S+ %                | GMT  |
| 2 doses of IMVANEX        |       | 92  | 5.4                | 1   | 75  | 92                 | 54  | 99                  | 125  |
| Licensed smallpox vaccine |       | 200 | 77                 | 22  | 195 | -                  | -   | 98                  | 190  |

<sup>1</sup>Day 0 corresponding to day of booster vaccination with IMVANEX (pre-booster); Day 7 and 14 corresponding to 1 or 2 weeks after booster vaccination with IMVANEX; N = number of subjects in the specific study group; ELISA = enzyme-linked immunosorbent assay; PRNT = plaque reduction neutralization test; S+ = Seropositivity rate; GMT = geometric mean titre.

### Paediatric population

The European Medicines Agency has deferred the obligation to submit the results of studies with IMVANEX in all subsets of the paediatric population for prevention of smallpox infection by active immunisation against smallpox infection and disease (see section 4.2 for information on paediatric use).

This medicinal product has been authorised under ‘exceptional circumstances’.

This means that due to the lack of smallpox disease in the world it has not been possible to obtain complete information on this medicinal product.

The European Medicines Agency will review any new information which may become available every year and this SmPC will be updated as necessary.

### 5.2 Pharmacokinetic properties

Not applicable.

### 5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on repeated dose toxicity, local tolerance, female fertility, embryo-foetal and postnatal toxicity.

## 6. PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Trometamol  
Sodium chloride  
Water for injections

### 6.2 Incompatibilities

In the absence of compatibility studies, this vaccine must not be mixed with other medicinal products.

### 6.3 Shelf life

2 years at -20°C +/-5°C  
4 years at -50°C +/-10°C  
5 years at -80°C +/-10°C

After thawing, the vaccine should be used immediately or can be stored at 2°C -8°C in the dark for up to 8 weeks prior to use.

Do not re-freeze a vial once it has been thawed.

#### **6.4 Special precautions for storage**

Store in a freezer (at -20°C +/-5°C or -50°C +/-10°C or -80°C +/-10°C). Expiry date depends on storage temperature.

Can be stored short-term in a refrigerator at 2°C–8°C for up to 8 weeks prior to use.

Store in the original package in order to protect from light.

#### **6.5 Nature and contents of container**

0.5 ml suspension in a vial (Type I glass) with stopper (bromobutyl rubber).

Pack size of 20.

#### **6.6 Special precautions for disposal and other handling**

The vaccine should be allowed to reach room temperature before use. Swirl the vial gently before use for at least 30 seconds.

The suspension should be visually inspected for particulate matter and discoloration before use. In the event of any damage to the vial, foreign particulate matter and/or variation of physical aspect being observed, discard the vaccine.

A dose of 0.5 ml is withdrawn into a syringe for injection.

Any unused vaccine or waste material should be disposed of in accordance with local requirements.

### **7. MARKETING AUTHORISATION HOLDER**

Bavarian Nordic A/S  
Hejreskovvej 10a  
DK-3490 Kvistgaard  
Denmark

### **8. MARKETING AUTHORISATION NUMBER(S)**

EU/1/13/855/001

### **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 31 July 2013

### **10. DATE OF REVISION OF THE TEXT**

{MM/YYYY}

Detailed information on this medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu>.

## **ANNEX II**

- A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**
- D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**
- E. SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE CONDITIONAL MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES**

**A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer(s) of the biological active substance(s)

Bavarian Nordic A/S  
Hejreskovvej 10 A, Kvistgård, 3490, Denmark

Name and address of the manufacturer(s) responsible for batch release

Bavarian Nordic A/S  
Hejreskovvej 10 A, Kvistgård, 3490, Denmark

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Medicinal product subject to medical prescription.

- **Official batch release**

In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.

**C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

- **Periodic Safety Update Reports**

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

**D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT**

- **Risk Management Plan (RMP)**

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the submission of a PSUR and the update of a RMP coincide, they can be submitted at the same time.

- **Obligation to conduct post-authorisation measures**

The MAH shall complete, within the stated timeframe, the below measures:

| Description   | Due date                            |
|---|-------------------------------------|
| Post-authorisation efficacy study (PAES) POX-MVA-006: A randomized, open-label Phase III non-inferiority trial to compare the immunogenicity of IMVAMUNE (MVA-BN) with the conventional smallpox vaccine ACAM2000 in 18-40 year old healthy vaccinia-naïve subjects | Final Clinical study report Q2 2018 |

**E. SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR THE MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES**

This being a marketing authorisation under exceptional circumstances and pursuant to Article 14(8) of Regulation (EC) No 726/2004, the MAH shall complete, within the stated timeframe, the following measures:

| Description  | Due date  |
|--|---|
| <p>To ensure adequate monitoring of safety and/or effectiveness, the applicant should perform the following studies to collect data where IMVANEX is used as a prophylactic vaccine and/or use in case of re-emergence of circulating smallpox.</p> <ul style="list-style-type: none"> <li>• Non-interventional post-authorisation safety study (PASS)<br/>POX-MVA-038: An observational, non-interventional post-authorisation safety study for the prophylactic vaccination with IMVANEX for [insert description of target vaccinee population]</li> <li>• Non-interventional post-authorisation efficacy study (PAES)<br/>POX-MVA-039: An observational, non-interventional post-authorisation safety and efficacy study for the prophylactic vaccination with IMVANEX following re-emergence of circulating smallpox infections</li> </ul> | Status to be reported annually within each annual re-assessment application |

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING**

**PACK OF 20 VIALS**

**1. NAME OF THE MEDICINAL PRODUCT**

IMVANEX suspension for injection  
Smallpox vaccine (Live Modified Vaccinia Virus Ankara)

**2. STATEMENT OF ACTIVE SUBSTANCE(S)**

1 dose (0.5 ml) has a titre of no less than  $5 \times 10^7$  Inf.U (Inf.U = infectious units)

**3. LIST OF EXCIPIENTS**

Trometamol  
Sodium chloride  
Water for injections

**4. PHARMACEUTICAL FORM AND CONTENTS**

Suspension for injection.

20 single dose vials.

**5. METHOD AND ROUTE(S) OF ADMINISTRATION**

Subcutaneous use.  
Thaw at room temperature. Gently swirl for at least 30 seconds.  
Read the package leaflet before use.

**6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN**

Keep out of the sight and reach of children.

**7. OTHER SPECIAL WARNING(S), IF NECESSARY**

**8. EXPIRY DATE**

Exp. (-20°C: +/-5°C):  
Exp. (-50°C +/-10°C):  
Exp. (-80°C +/-10°C):



**9. SPECIAL STORAGE CONDITIONS**

Store in a freezer (at -20°C +/-5°C or -50°C +/-10°C or -80°C +/-10°C) protected from light. Expiry date depends on storage temperature.

**10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Dispose of in accordance with local requirement.

**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Bavarian Nordic A/S  
Hejreskovvej 10a  
3490 Kvistgaard  
Denmark

**12. MARKETING AUTHORISATION NUMBER(S)**

EU/1/13/855/001

**13. BATCH NUMBER<, DONATION AND PRODUCT CODES>**

Lot:

**14. GENERAL CLASSIFICATION FOR SUPPLY**

Medicinal product subject to medical prescription.

**15. INSTRUCTIONS ON USE**

**16. INFORMATION IN BRAILLE**

Justification for not including Braille accepted

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**VIAL**

**1. NAME OF THE MEDICINAL PRODUCT**

IMVANEX<sup>®</sup> suspension for injection  
Smallpox vaccine

**2. METHOD OF ADMINISTRATION**

Subcutaneous use

**3. EXPIRY DATE**

Exp. (-20°C: +/-5°C):  
Exp. (-50°C +/-10°C):  
Exp. (-80°C +/-10°C):

**4. BATCH NUMBER**

Lot:

**5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT**

1 dose (0.5 ml)

**6. OTHER**

Store in a freezer (at -20°C +/-5°C or -50°C +/-10°C or -80°C +/-10°C) protected from light.

**B. PACKAGE LEAFLET**

## Package leaflet: Information for the user

### IMVANEX suspension for injection

Smallpox vaccine (Live Modified Vaccinia Virus Ankara)

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

**Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.**

- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or nurse.
- If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

#### What is in this leaflet

1. What IMVANEX is and what it is used for
2. What you need to know before you receive IMVANEX
3. How IMVANEX is given
4. Possible side effects
5. How to store IMVANEX
6. Contents of the pack and other information

#### 1. What IMVANEX is and what it is used for

IMVANEX is a vaccine used to prevent smallpox infection in adults.

When a person is given the vaccine, the immune system (the body's natural defence system) will produce its own protection in the form of antibodies against the smallpox virus.

IMVANEX does not contain smallpox virus (Variola) and cannot spread or cause smallpox.

#### 2. What you need to know before you receive IMVANEX

##### You must not receive IMVANEX:

- If you have previously had a sudden life-threatening allergic reaction to any ingredient of Imvanex (these are listed in section 6) or chicken protein, benzonase or gentamicin which may be present in the vaccine in very small amounts.
- If you are ill with a high temperature. In this case, your doctor will postpone the vaccination until you are feeling better. The presence of a minor infection, such as a cold, should not require postponement of the vaccination, but talk to your doctor or nurse first.

#### Warnings and precautions

Tell your doctor or nurse before you receive IMVANEX:

- if you have atopic dermatitis (see section 4).
- if you have HIV infection or any other condition or treatment leading to a weakened immune system

The protective efficacy of IMVANEX against smallpox has not been studied.

IMVANEX may not fully protect all people who are vaccinated.

Prior vaccination with IMVANEX may modify the cutaneous response ('take') to subsequently administered replication-competent smallpox vaccine resulting in a reduced or absent take.

### **Other medicines or vaccines and IMVANEX**

Tell your doctor or nurse if you are taking or have recently taken any other medicines or if you have recently received any other vaccine.

### **Pregnancy and breast-feeding**

If you are a pregnant or breast feeding, think you may be pregnant or are planning to have a baby, talk to your doctor. The use of this vaccine during pregnancy and breast-feeding is not recommended. However, your doctor will assess whether the possible benefit in terms of preventing smallpox would outweigh the potential risks of giving you this vaccine.

### **Driving and using machines**

There is no information on the effect of IMVANEX on your ability to drive or use machines. However, it is possible that if you experience any of the side effects listed in section 4, then some of these may affect your ability to drive or use machines (e.g. dizziness).

### **IMVANEX contains Sodium**

This medicinal product contains less than 1mmol sodium (23 mg) per dose and is therefore essentially "sodium-free".

## **3. How IMVANEX is given**

You can be given this vaccine whether or not you have received smallpox vaccination in the past.

The vaccine will be injected under the skin, preferably into the upper arm, by your doctor or a nurse. It must not be injected into a blood vessel.

#### **If you have never been vaccinated against smallpox:**

- You will receive two injections.
- The second injection will be given no less than 28 days after the first.
- Make sure you complete the vaccination course of two injections.

#### **If you have previously been vaccinated against smallpox:**

- You will receive one injection.
- If your immune system is weakened you will receive two injections with the second injection no less than 28 days after the first.

### **If you forget to receive IMVANEX**

If you miss a scheduled injection, tell your doctor or nurse and arrange another visit.

If you have any further questions on the use of this vaccine, ask your doctor or nurse.

#### 4. Possible side effects

Like all medicines, this vaccine can cause side effects, although not everybody gets them.

##### **Serious side effects**

Contact a doctor immediately, or go immediately to the emergency department of your nearest hospital if you experience any of the following symptoms:

- difficulty in breathing
- dizziness
- swelling of the face and neck.

These symptoms may be a sign of a serious allergic reaction.

##### **Other side effects**

If you already have atopic dermatitis, you may experience more intense local skin reactions (such as redness, swelling and itching) and other general symptoms (such as headache, muscle pain, feeling sick or tired), as well as a flare-up or worsening of your skin condition.

The most common side effects reported were at the site of injection. Most of them were mild to moderate in nature and resolved without any treatment within seven days.

If you get any of the following side effects, tell your doctor.

**Very common** (may affect more than 1 in 10 people):

- headache,
- aching muscles,
- feeling sick,
- tiredness,
- pain, redness, swelling, hardness or itching at the injection site.

**Common** (may affect up to 1 in 10 people):

- chills,
- fever,
- joint pain, pain in extremities,
- loss of appetite,
- discolouration, lump or bruising at the injection site.

**Uncommon** (may affect up to 1 in 100 people):

- nose and throat infection, upper respiratory tract infection,
- swollen lymph nodes,
- abnormal sleep,
- dizziness, abnormal skin sensations,
- muscle stiffness, back pain, neck pain,
- sore throat, runny nose, cough,
- diarrhoea, vomiting, abdominal pain, dry mouth,
- rash, itch, skin inflammation, skin discolouration,
- warmth, bleeding, irritation, scaling, inflammation, abnormal skin sensation, reaction,
- underarm swelling, flushing, chest pain, pain in the armpit,
- increase of cardiac laboratory values (like Troponin I ), liver enzyme increased, white blood cell count decreased, mean platelet volume decreased
- bruising.

**Rare** (may affect up to 1 in 1000 people):

- sinus infection
- pink eye
- influenza
- hives (nettle rash)
- skin bruising
- sweating
- night sweats
- lump in skin
- muscle cramps
- muscle pain
- muscle weakness
- swelling of the ankles, feet or fingers
- faster heart beat
- spinning sensation (vertigo)
- migraine
- nerve disorder causing weakness, tingling or numbness, drowsiness
- rash, numbness, dryness, movement impairment, vesicles at injection site
- weakness
- feeling unwell
- influenza like illness
- swelling of the face, mouth and throat
- white blood cell count increased

### **Reporting of side effects**

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via [the national reporting system listed in Appendix V](#). By reporting side effects you can help provide more information on the safety of this medicine.

## **5. How to store IMVANEX**

Keep this medicine out of the sight and reach of children.

Do not use this vaccine after the expiry date which is stated on the label after Exp. The expiry date refers to the last day of that month.

Store in a freezer (at  $-20^{\circ}\text{C} \pm 5^{\circ}\text{C}$  or  $-50^{\circ}\text{C} \pm 10^{\circ}\text{C}$  or  $-80^{\circ}\text{C} \pm 10^{\circ}\text{C}$ ). Expiry date depends on storage temperature. Do not refreeze the vaccine once thawed. After thawing, the vaccine should be used immediately or can be stored at  $2^{\circ}\text{C} - 8^{\circ}\text{C}$  in the dark for up to 8 weeks prior to use.

Store in the original package to protect from light.

## **6. Contents of the pack and other information**

### **What IMVANEX contains**

One dose (0.5 ml) contains:

The active substance is Modified Vaccinia Ankara – Bavarian Nordic Live virus<sup>1</sup>, no less than  $5 \times 10^7$  Inf.U\*  
\*infectious units

<sup>1</sup>Produced in chick-embryo cells

The other ingredients are: trometamol, sodium chloride, and water for injections.

This vaccine contains trace residues of gentamicin and benzonase.

### **What IMVANEX looks like and contents of the pack**

Once the frozen vaccine has been thawed, IMVANEX is a pale milky coloured homogeneous suspension for injection.

IMVANEX is provided as a suspension for injection in a vial (0.5 ml).  
IMVANEX is available in pack containing 20 vials.

### **Marketing Authorisation Holder and Manufacturer**

Bavarian Nordic A/S  
Hejreskovvej 10A,  
3490 Kvistgaard  
Denmark  
tel +45 3326 8383  
fax +45 3326 8380  
e-mail [regulatory@bavarian-nordic.com](mailto:regulatory@bavarian-nordic.com)

### **This leaflet was last revised in {MM/YYYY}**

This medicine has been authorised under ‘exceptional circumstances’.

This means that due to scientific reasons it has been impossible to get complete information on this medicine.

The European Medicines Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.

Detailed information on this medicine is available on the European Medicines Agency web site:  
<http://www.ema.europa.eu>

---

### **The following information is intended for healthcare professionals only:**

#### **Instructions for preparation and administration of the vaccine:**

The vaccine should be allowed to reach room temperature before use. Swirl gently before use. Visually inspect the suspension prior to administration. In case of any particles and/or abnormal appearance, the vaccine should be discarded.

A dose of 0.5 ml is withdrawn into a syringe for injection.

After thawing, the vaccine should be used immediately or can be stored at 2°C–8°C in the dark for up to 8 weeks prior to use.

Do not refreeze the vaccine once thawed.

In the absence of compatibility studies, this vaccine must not be mixed with other vaccines.